

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5724675

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
SIAMAB THERAPEUTICS, INC.	09/09/2019

RECEIVING PARTY DATA

Name:	SEATTLE GENETICS, INC.
Street Address:	21823 30TH DRIVE SE
City:	BOTHELL
State/Country:	WASHINGTON
Postal Code:	98021

PROPERTY NUMBERS Total: 66

Property Type	Number
Application Number:	14138879
Application Number:	13007237
Application Number:	61295386
Application Number:	14050773
Application Number:	15002674
Application Number:	15206688
Application Number:	61620414
Application Number:	15028360
Application Number:	61889274
Application Number:	61935549
Application Number:	61941763
Application Number:	61975347
Application Number:	62062460
Application Number:	15518179
Application Number:	62062474
Application Number:	62102545
Application Number:	62173555
Application Number:	62187568
Application Number:	15518214
Application Number:	62078610

PATENT

Property Type	Number
Application Number:	62102527
Application Number:	62173560
Application Number:	62187587
Application Number:	15526593
Application Number:	14987432
Application Number:	62145214
Application Number:	62174700
Application Number:	62287679
Application Number:	62293872
Application Number:	15735812
Application Number:	62254278
Application Number:	62274572
Application Number:	62287666
Application Number:	62293989
Application Number:	62345515
Application Number:	62382835
Application Number:	15775410
Application Number:	62423575
Application Number:	62443935
Application Number:	62480077
Application Number:	16462075
Application Number:	62345470
Application Number:	16073349
Application Number:	62423597
Application Number:	62443936
Application Number:	62480096
Application Number:	62486817
Application Number:	62563715
Application Number:	16462084
Application Number:	62466766
Application Number:	62480126
Application Number:	62486826
Application Number:	62563718
PCT Number:	US2011021387
PCT Number:	US2013029240
PCT Number:	US2014060079
PCT Number:	US2015054877
PCT Number:	US2015054936

Property Type	Number
PCT Number:	US2015060287
PCT Number:	US2016036907
PCT Number:	US2016061427
PCT Number:	US2017062155
PCT Number:	US2017015301
PCT Number:	US2017062156
PCT Number:	US2018020562
Application Number:	62577830

CORRESPONDENCE DATA

Fax Number: (617)812-1277

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4148476401

Email: docketing@mcneillbaur.com

Correspondent Name: MCNEILL BAUR PLLC

Address Line 1: 500 W. SILVER SPRING DRIVE

Address Line 2: SUITE K-200

Address Line 4: GLENDALE, WISCONSIN 53217

ATTORNEY DOCKET NUMBER: 01218-0998

NAME OF SUBMITTER: JENNIFER L. ARGUELLES

SIGNATURE: /Jennifer L. Arguelles/

DATE SIGNED: 09/18/2019

Total Attachments: 10

source=2019-09-11_Amended_and_Restated_IP_Assignment_Agreement#page1.tif
source=2019-09-11_Amended_and_Restated_IP_Assignment_Agreement#page2.tif
source=2019-09-11_Amended_and_Restated_IP_Assignment_Agreement#page3.tif
source=2019-09-11_Amended_and_Restated_IP_Assignment_Agreement#page4.tif
source=2019-09-11_Amended_and_Restated_IP_Assignment_Agreement#page5.tif
source=2019-09-11_Amended_and_Restated_IP_Assignment_Agreement#page6.tif
source=2019-09-11_Amended_and_Restated_IP_Assignment_Agreement#page7.tif
source=2019-09-11_Amended_and_Restated_IP_Assignment_Agreement#page8.tif
source=2019-09-11_Amended_and_Restated_IP_Assignment_Agreement#page9.tif
source=2019-09-11_Amended_and_Restated_IP_Assignment_Agreement#page10.tif

AMENDED AND RESTATED INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

This Amended and Restated Intellectual Property Assignment Agreement (this "AR IP Assignment") is effective, as of this 15th day of August, 2019, is made by Siamab Therapeutics, Inc., a Delaware corporation ("Seller"), located at 90 Bridge Street, Newton, MA 02458, in favor of Seattle Genetics, Inc., a Delaware corporation ("Buyer"), located at 21823 30th Drive SE, Bothell, WA 98021, the purchaser of certain assets of Seller pursuant to that certain Asset Purchase Agreement of even date herewith by and among Buyer, Seller and the Stockholder Representative named therein (the "Asset Purchase Agreement").

WHEREAS, under the terms of the Asset Purchase Agreement, Seller has conveyed, transferred, and assigned to Buyer, among other assets, certain intellectual property of Seller, and has agreed to execute and deliver this IP Assignment for recording with the United States Patent and Trademark Office, and corresponding entities or agencies in any applicable jurisdictions;

WHEREAS, the Intellectual Property Assignment Agreement, dated 15th day of August 2019, previously executed by Seller and Buyer (the "Prior IP Assignment") inadvertently omitted certain of the Purchased Patents and contained certain other clerical errors.

WHEREAS, the parties wish to enter into this AR IP Assignment to be effective on the 15th day of August 2019, and to supersede the Prior IP Assignment in its entirety effective as of such date.

NOW THEREFORE, Seller agrees as follows:

1. Assignment. For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Seller hereby irrevocably conveys, transfers, and assigns to Buyer, and Buyer hereby accepts, all of Seller's right, title, and interest in and to the following (the "Assigned IP"):

(a) the patents and patent applications set forth on Schedule 1 hereto and all issuances, divisions, continuations, continuations-in-part, reissues, extensions, reexaminations, renewals and all rights in any priority filings thereto and any rights of priority therein (the "Purchased Patents");

(b) all rights of any kind whatsoever of Seller accruing under any of the Purchased Patents provided by applicable law of any jurisdiction, by international treaties and conventions, and otherwise throughout the world;

(c) any and all royalties, fees, income, payments, and other proceeds now or hereafter due or payable with respect to any and all of the Purchased Patents; and

(d) any and all claims and causes of action with respect to any of the Purchased Patents, whether accruing before, on, or after the date hereof, including all rights to and claims for damages, restitution, and injunctive and other legal and equitable relief for past, present, and future infringement, dilution, misappropriation, violation, misuse, breach, or default, with the right but no obligation to sue for such legal and equitable relief and to collect, or otherwise recover, any such damages; provided, however, that the foregoing shall not include any rights of Seller under the Asset Purchase Agreement (including in respect of claims involving Buyer thereunder).

2. Recordation and Further Actions. Seller hereby authorizes the Commissioner for Patents and the Commissioner for Trademarks in the United States Patent and Trademark Office, to record and register this AR IP Assignment upon request by Buyer. Following the date hereof, upon Buyer's

reasonable request and at Buyer's sole cost and expense, Seller shall take such steps and actions, and provide such cooperation and assistance to Buyer and its successors, assigns, and legal representatives, including the execution and delivery of any affidavits, declarations, oaths, exhibits, assignments, powers of attorney, or other documents, as may be reasonably necessary to effect, evidence, or perfect the assignment of the Assigned IP to Buyer, or any assignee or successor thereto.

3. Terms of the Asset Purchase Agreement. The parties hereto acknowledge and agree that this AR IP Assignment is entered into pursuant to the Asset Purchase Agreement, to which reference is made for a further statement of the rights and obligations of Seller and Buyer with respect to the Assigned IP. The representations, warranties, covenants, agreements, and indemnities contained in the Asset Purchase Agreement shall not be superseded hereby but shall remain in full force and effect to the full extent provided therein. In the event of any conflict or inconsistency between the terms of the Asset Purchase Agreement and the terms hereof, the terms of the Asset Purchase Agreement shall govern.

4. Counterparts. This AR IP Assignment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed one and the same agreement. A signed copy of this AR IP Assignment delivered by facsimile, e-mail, or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this AR IP Assignment.

5. Successors and Assigns. This AR IP Assignment shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns.

6. Governing Law. This IP Assignment and any claim, controversy, dispute, or cause of action (whether in contract, tort, or otherwise) based upon, arising out of, or relating to this AR IP Assignment and the transactions contemplated hereby shall be governed by, and construed in accordance with, the laws of the United States and the State of New York, without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction).

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, Seller has duly executed and delivered this AR IP Assignment as of the date first above written.

SIAMAB THERAPEUTICS, INC.

By: Jeff Behrens

Name: Jeff Behrens

Title: Chief Executive Officer and President

Address for Notices:

90 Bridge Street

Newton, MA 02458

Email: jeff@siamab.com

Attention: Chief Executive Officer

ACKNOWLEDGMENT


COMMONWEALTH OF MASSACHUSETTS)
)SS.
)

COUNTY OF MIDDLESEX

On the 9 day of September, 2019, before me personally appeared Jeff Behrens, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the foregoing instrument, who, being duly sworn, did depose and say that he executed the same in his authorized capacity as an officer of Siamab Therapeutics, Inc., a Delaware corporation, and acknowledged the instrument to be the free act and deed of Siamab Therapeutics, Inc. for the uses and purposes mentioned in the instrument.

Jenna Stein
Notary Public
Printed Name: Jenna Stein

My Commission Expires:



[Signature page to Intellectual Property Assignment Agreement]

AGREED TO AND ACCEPTED:

SEATTLE GENETICS, INC.

By: Clay B. Siegall
Name: Clay B. Siegall, Ph.D.
Title: President, Chief Executive Officer and
Chairman of the Board

Address for Notices:
21823 30th Drive SE
Bothell, WA 98021
E-mail: csiegall@seagen.com
Attention: Clay B. Siegall, Ph.D.

ACKNOWLEDGMENT

STATE OF WASHINGTON)
)SS.
COUNTY OF KING)

On the 11th day of September 2019, before me personally appeared Clay B. Siegall, Ph.D., personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the foregoing instrument, who, being duly sworn, did depose and say that he executed the same in his authorized capacity as an officer of Seattle Genetics, Inc., a Delaware corporation, and acknowledged the instrument to be the free act and deed of Seattle Genetics, Inc. for the uses and purposes mentioned in the instrument.

Robin L. Parmelee
Notary Public Robin L. Parmelee
Printed Name:

My Commission Expires: 11/25/2020



[Signature page to Intellectual Property Assignment Agreement]

SCHEDULE 1

PURCHASED PATENTS

Jurisdiction	Application No./ Pub No./ Patent No.	Filing Date/ Pub Date/ Grant Date	Application Title
CN	201180010659.X	14-Jan-2011 23-Jan-2013	COMPOSITIONS AND METHODS FOR DETECTING CANCER
DE	13184707.1 2680004 2680004	17-Sep-2013 01-Jan-2014 31-Aug-2016	METHODS FOR DETECTING CANCER
EP	11733477.1 2524233	14-Jan-2011 21-Nov-2012	COMPOSITIONS AND METHODS FOR DETECTING CANCER
EP	13184707.1 2680004 2680004	17-Sep-2013 01-Jan-2014 31-Aug-2016	METHODS FOR DETECTING CANCER
PCT	PCT/US2011/021387 WO2011088385	14-Jan-2011 21-Jul-2011	COMPOSITIONS AND METHODS FOR DETECTING CANCER
US	14/138,879 20140113979 9423401	23-Dec-2013 24-Apr-2014 23-Aug-2016	COMPOSITIONS AND METHODS FOR DETECTING CANCER
US	13/007,237 20110177614	14-Jan-2011 21-Jul-2011	COMPOSITIONS AND METHODS FOR DETECTING CANCER
US	61/295,386	15-Jan-2010	COMPOSITIONS AND METHODS FOR DETECTING CANCER
PCT	PCT/US2013/029240 WO2013151649	06-Mar-2013 10-Oct-2013	GLYCAN-INTERACTING COMPOUNDS
US	14/050,773 20140178365	10-Oct-2013 26-Jun-2014	GLYCAN-INTERACTING COMPOUNDS

Schedule 1 to Intellectual Property Assignment Agreement

	9273142	01-Mar-2016	
US	15/002,674 20160137743 9416194	21-Jan-2016 19-May-2016 16-Aug-2016	GLYCAN-INTERACTING COMPOUNDS
US	15/206,688 20160311922	11-Jul-2016 27-Oct-2016	GLYCAN-INTERACTING COMPOUNDS
US	61/620,414	04-Apr-2012	MONOCLONAL ANTIBODIES AND METHODS FOR TREATING CANCER
EP	14852277.4 3054974	10-Oct-2014 17-Aug-2016	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	15/028,360 20160264684	08-Apr-2016 15-Sep-2016	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	61/889,274	10-Oct-2013	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	61/935,549	04-Feb-2014	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	61/941,763	19-Feb-2014	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	61/975,347	04-Apr-2014	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
PCT	PCT/US2014/060079 WO2015054600	10-Oct-2014 16-Apr-2015	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	62/062,460	10-Oct-2014	GLYCAN ANALYSIS AND PROFILING
PCT	PCT/US2015/054877 WO2016057890	09-Oct-2015 14-Apr-2016	GLYCAN ANALYSIS AND PROFILING
EP	15848503.7 3204537	09-Oct-2015 16-Aug-2017	GLYCAN ANALYSIS AND PROFILING
US	15/518,179 20170305950	10-Apr-2017 26-Oct-2017	GLYCAN ANALYSIS AND PROFILING
US	62/062,474	10-Oct-2014	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE

Schedule 1 to Intellectual Property Assignment Agreement

US	62/102,545	12-Jan-2015	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	62/173,555	10-Jun-2015	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	62/187,568	01-Jul-2015	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
PCT	PCT/US2015/054936 WO2016057916	09-Oct-2015 14-Apr-2016	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	15/518,214 20180280504	10-Apr-2017 04-Oct-2018	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	62/078,610	12-Nov-2014	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	62/102,527	12-Jan-2015	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	62/173,560	10-Jun-2015	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	62/187,587	01-Jul-2015	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
PCT	PCT/US2015/060287 WO2016077526	12-Nov-2015 19-May-2016	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
CA	2967595 2967595	12-Nov-2015 19-May-2016	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
EP	15859152.9 3218005	12-Nov-2015 20-Sep-2017	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
IL	251988	12-Nov-2015	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
JP	2017-526592 2018-503600	12-Nov-2015 08-Feb-2018	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
MX	MX/a/2017/006167 MX/a/2017/006167	12-Nov-2015 05-Apr-2018	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	15/526,593 20170306046	12-May-2017 26-Oct-2017	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE

Schedule 1 to Intellectual Property Assignment Agreement

US	14/987,432 20160130356 9879087	04-Jan-2016 12-May-2016 30-Jan-2018	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	62/145,214	09-Apr-2015	COMPOSITIONS AND METHODS FOR TARGETING CANCER STEM CELLS
US	62/174,700	12-Jun-2015	COMPOSITIONS AND METHODS FOR TARGETING CANCER STEM CELLS
US	62/287,679	27-Jan-2016	COMPOSITIONS AND METHODS FOR TARGETING CANCER STEM CELLS
US	62/293,872	11-Feb-2016	COMPOSITIONS AND METHODS FOR TARGETING CANCER STEM CELLS
PCT	PCT/US2016/036907 WO2016201240	10-Jun-2016 15-Dec-2016	COMPOSITIONS AND METHODS FOR TARGETING CANCER STEM CELLS
US	15/735,812	12-Dec-2017	COMPOSITIONS AND METHODS FOR TARGETING CANCER STEM CELLS
US	62/254,278	12-Nov-2015	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	62/274,572	04-Jan-2016	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	62/287,666	27-Jan-2016	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	62/293,989	11-Feb-2016	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	62/345,515	03-Jun-2016	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	62/382,835	02-Sep-2016	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
PCT	PCT/US2016/061427 WO2017083582	10-Nov-2016 18-May-2017	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
AU	2016353153	10-Nov-2016	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
CA	3002097 3002097	10-Nov-2016 18-May-2017	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE

Schedule 1 to Intellectual Property Assignment Agreement

CN	2016800787048 108463248	10-Nov-2016 28-Aug-2018	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
EP	16865044.8 EP3373969	10-Nov-2016 19-Sep-2018	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
HK	18112429.6	27-Sep-2018	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
IL	258768	10-Nov-2016	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
JP	2018-524357 2019-500020	10-Nov-2016 10-Jan-2019	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
KR	10-2018-7013532	10-Nov-2016	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
MX	MX/a/2018/005061 MX/a/2018/005061	10-Nov-2016 15-Mar-2019	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
SG	11201803213X	10-Nov-2016	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	15/775,410 20180327509	11-May-2018 15-Nov-2018	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
ZA	2018/02692	10-Nov-2016	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
EP	17872341.7	17-Nov-2017	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	62/423,575	17-Nov-2016	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	62/443,935	09-Jan-2017	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	62/480,077	31-Mar-2017	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	16/462,075	17-May-2019	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
PCT	PCT/US2017/062155	17-Nov-2017	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE

Schedule 1 to Intellectual Property Assignment Agreement

	WO2018094143	24-May-2018	
US	62/345,470	03-Jun-2016	COMPOSITIONS AND METHODS FOR TARGETING CANCER STEM CELLS
US	16/073,349 20190031780	27-Jul-2018 31-Jan-2019	COMPOSITIONS AND METHODS FOR TARGETING CANCER STEM CELLS
PCT	PCT/US2017/015301 WO2017132486	27-Jan-2017 03-Aug-2017	COMPOSITIONS AND METHODS FOR TARGETING CANCER STEM CELLS
EP	17871763.3	17-Nov-2017	COMPOSITIONS AND METHODS FOR TREATING CANCER
US	62/423,597	17-Nov-2016	COMPOSITIONS AND METHODS FOR TREATING CANCER
US	62/443,936	09-Jan-2017	COMPOSITIONS AND METHODS FOR TREATING CANCER
US	62/480,096	31-Mar-2017	COMPOSITIONS AND METHODS FOR TREATING CANCER
US	62/486,817	18-Apr-2017	COMPOSITIONS AND METHODS FOR TREATING CANCER
US	62/563,715	27-Sep-2017	COMPOSITIONS AND METHODS FOR TREATING CANCER
US	16/462,084	17-May-2019	COMPOSITIONS AND METHODS FOR TREATING CANCER
PCT	PCT/US2017/062156 WO2018094144	17-Nov-2017 24-May-2018	COMPOSITIONS AND METHODS FOR TREATING CANCER
PCT	PCT/US2018/020562 WO2018160909	02-Mar-2018 07-Sep-2018	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	62/466,766	03-Mar-2017	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	62/480,126	31-Mar-2017	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	62/486,826	18-Apr-2017	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	62/563,718	27-Sep-2017	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
US	62/577,830	27-Oct-2017	GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE

Schedule 1 to Intellectual Property Assignment Agreement